🇺🇸 FDA
Patent

US 11446302

Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

granted A61KA61K31/436A61K31/517

Quick answer

US patent 11446302 (Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations) held by The Board of Regents of the University of Texas System expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/436, A61K31/517, A61K31/519, A61K31/7088